Lakefront Biotherapeutics
No trades
No trades
Compare with Lakefront Biotherapeutics
8.67 USD
362.14 M USD
1.26 B USD
49.19 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Profile
Sector
Industry
CEO
Henry O. Gosebruch
Website
Headquarters
Mechelen
Founded
1999
IPO date
May 6, 2005
ISIN
US36315X1019
CUSIP
36315X101
FIGI
BBG000BJQY75
Identifiers
ISIN US36315X1019
Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Weight0.10%
Market value8.97 M
Weight1.04%
Market value2.09 M
Weight0.05%
Market value574.03 K
Weight0.03%
Market value355.74 K
Weight0.03%
Market value355.74 K
Weight0.07%
Market value214.57 K
Weight0.03%
Market value157.93 K
Weight0.53%
Market value116.71 K
Weight0.34%
Market value48.01 K
Weight0.03%
Market value23.59 K
Weight0.03%
Market value20.45 K
Explore more ETFs